When to Stop Mircera in Hemodialysis Patients
Discontinue Mircera when hemoglobin continues to rise despite a 25% dose reduction, and restart only when hemoglobin begins to decrease, using a dose approximately 25% below the previously administered dose. 1
Primary Stopping Criteria
Immediate Discontinuation Required When:
Hemoglobin continues rising after dose reduction: If you've already reduced Mircera by 25% due to rapid hemoglobin rise (>1 g/dL in 2 weeks) and hemoglobin keeps climbing, stop the drug completely 1
Hemoglobin approaches or exceeds 11 g/dL: For hemodialysis patients, reduce or interrupt Mircera when hemoglobin reaches this threshold 1
Non-response after 12 weeks of dose escalation: If hemoglobin hasn't increased by more than 1 g/dL despite escalating doses over 12 weeks, further increases are unlikely to help and may increase risks. Discontinue and evaluate other causes of anemia 1
Restart Algorithm After Discontinuation
Monitor hemoglobin every 2 weeks after withholding Mircera 2. The time to hemoglobin decline is variable and unpredictable—median 7 weeks for long-acting ESAs (range 2-13 weeks) 3.
When restarting:
- Wait until hemoglobin begins to decrease and approaches the upper limit of acceptable range
- Restart at a dose approximately 25% below the previously administered dose 1
- The rate of hemoglobin fall should guide timing of restart 2
Critical Safety Context
The FDA label emphasizes that no trial has identified a hemoglobin target, ESA dose, or dosing strategy that eliminates increased risks of death, serious cardiovascular events, and stroke when targeting hemoglobin >11 g/dL 1. This makes aggressive continuation of Mircera when hemoglobin exceeds target particularly dangerous.
Common Pitfalls to Avoid
Do not simply reduce doses indefinitely without stopping: The KDOQI guidelines note uncertainty about withholding ESAs, but the FDA label is explicit—if hemoglobin continues rising after dose reduction, discontinuation is required 2, 1
Avoid the temptation to continue dosing to prevent hemoglobin drops: While older KDOQI guidance expressed concern about hemoglobin falling below target if ESAs are withheld, this must be balanced against the cardiovascular risks of excessive hemoglobin levels 2. The FDA label prioritizes safety over maintaining stable levels 1.
Don't wait for hemoglobin to reach dangerous levels: Act when hemoglobin approaches 11 g/dL, not after it significantly exceeds this threshold 1
Additional Discontinuation Scenario
Pure red cell aplasia (PRCA): Though rare, if a patient develops sudden severe transfusion-dependent anemia despite Mircera therapy, consider antibody-mediated PRCA. This requires permanent discontinuation of subcutaneous Mircera, though intravenous administration may be possible after immunosuppressive therapy 4.